BRAF and melanoma: However, while the high frequency of BRAF mutations (20–30%) and excellent objective response rate (ORR 60–70%) indicate the clinical value of BRAF-targeted therapy, the remaining 80% of melanoma patients do not benefit from targeted therapy.